{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:19:35Z","timestamp":1783948775714,"version":"3.55.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014232","name":"Norwegian Directorate of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014232","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","drugandalcoholdependence.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.drugalcdep.2016.12.013","type":"journal-article","created":{"date-parts":[[2017,1,28]],"date-time":"2017-01-28T04:45:32Z","timestamp":1485578732000},"page":"17-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Rapid widespread distribution of intranasal naloxone for overdose prevention"],"prefix":"10.1016","volume":"173","author":[{"given":"Desiree","family":"Madah-Amiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Clausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Lobmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0005","series-title":"Narkotikautl\u00f8ste d\u00f8dsfall","author":"Amundsen","year":"2015"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0010","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jemermed.2005.03.007","article-title":"Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting","volume":"29","author":"Barton","year":"2005","journal-title":"J. Emerg. Med."},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0015","series-title":"Evaluation of the Take Home Naloxone Demonstration Project. Department of Strategic Planning, Finance and Performance","author":"Bennett","year":"2011"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0020","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1007\/s11524-011-9600-7","article-title":"Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania","volume":"88","author":"Bennett","year":"2011","journal-title":"J. Urban Health"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0025","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/add.13265","article-title":"Effectiveness of Scotland's national naloxone programme for reducing opioid-related deaths: a before (2006\u201310) versus after (2011\u201313) comparison","volume":"111","author":"Bird","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0030","first-page":"66","article-title":"Take-home naloxone to prevent fatalities from opiate-overdose: protocol for Scotland\u2019s public health policy evaluation, and a new measure to assess impact","volume":"22","author":"Bird","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/ADM.0000000000000034","article-title":"A systematic review of community opioid overdose prevention and naloxone distribution programs","volume":"8","author":"Clark","year":"2014","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0040","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.drugalcdep.2007.11.003","article-title":"Mortality prior to, during and after opioid maintenance treatment (OMT): A national prospective cross-registry study","volume":"94","author":"Clausen","year":"2008","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0045","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1197\/j.aem.2007.04.005","article-title":"Identifying injection drug users at risk of nonfatal overdose","volume":"14","author":"Coffin","year":"2007","journal-title":"Acad. Emerg. Med."},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0050","series-title":"Underestimated and Overlooked: A Global Review of Drug Overdose and Overdose Prevention. Global State of Harm Reduction 2010: Key Issues for Broadening the Response","first-page":"113","author":"Coffin","year":"2010"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0055","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/j.1360-0443.1997.tb03681.x","article-title":"The distribution of naloxone to heroin users","volume":"92","author":"Darke","year":"1997","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0060","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.10.013","article-title":"Legal changes to increase access to naloxone for opioid overdose reversal in the United States","volume":"157","author":"Davis","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0065","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/jlme.12208","article-title":"Lessons learned from the expansion of naloxone access in Massachusetts and North Carolina","volume":"43","author":"Davis","year":"2015","journal-title":"J. Law Med. Ethics"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0070","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/bmj.322.7291.895","article-title":"Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes","volume":"322","author":"Dettmer","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0075","series-title":"European Drug Report 2016","author":"European Monitoring Center for Drugs and Drug Addiction (EMCDDA)","year":"2016"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0080","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40122-015-0035-9","article-title":"Comparative usability study of a novel auto-injector and an intranasal system for naloxone delivery","volume":"4","author":"Edwards","year":"2015","journal-title":"Pain Ther."},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0085","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s11524-010-9495-8","article-title":"Overdose prevention and naloxone prescription for opioid users in San Francisco","volume":"87","author":"Enteen","year":"2010","journal-title":"J. Urban Health"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0090","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/aje\/kwr318","article-title":"Mortality among young injection drug users in San Francisco: a 10-year follow-up of the UFO study","volume":"175","author":"Evans","year":"2012","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0095","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1403494812472007","article-title":"Diversity in causes and characteristics of drug-induced deaths in an urban setting","volume":"41","author":"Gjersing","year":"2013","journal-title":"Scand. J. Public Health"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0100","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/003335490712200313","article-title":"Providing naloxone to substance users for secondary administration to reduce overdose mortality in New York City","volume":"122","author":"Heller","year":"2007","journal-title":"Public Health Rep."},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0105","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.drugpo.2014.01.005","article-title":"Effective use of naloxone among people who inject drugs in Kyrgyzstan and Tajikistan using pharmacy- and community-based distribution approaches","volume":"25","author":"Kan","year":"2014","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0110","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1111\/j.1360-0443.2009.02724.x","article-title":"Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose","volume":"104","author":"Kerr","year":"2009","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0115","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.addbeh.2012.01.019","article-title":"Incidence and risk factors for non-fatal overdose among a cohort of recently incarcerated illicit drug users","volume":"37","author":"Kinner","year":"2012","journal-title":"Addict. Behav."},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0120","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/jcph.759","article-title":"Pharmacokinetic properties and human use characteristics of an FDA approved intranasal naloxone product for the treatment of opioid overdose","volume":"56","author":"Krieter","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0125","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.drugpo.2014.02.003","article-title":"Making change happen: a case study of the successful establishment of a peer-administered naloxone program in one Australian jurisdiction","volume":"25","author":"Lancaster","year":"2014","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0130","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.17269\/cjph.104.3788","article-title":"Development and implementation of an opioid overdose prevention and response program in Toronto, Ontario","volume":"104","author":"Leece","year":"2013","journal-title":"Can. J. Public Health"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0135","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/dar.12198","article-title":"Working together: expanding the availability of naloxone for peer administration to prevent opioid overdose deaths in the Australian Capital Territory and beyond","volume":"34","author":"Lenton","year":"2014","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0140","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/add.13261","article-title":"Radical red tape reduction by government supported nasal naloxone: the Norwegian pilot project is innovative, safe and an important contribution to further development and dissemination of take-home naloxone","volume":"111","author":"Lobmaier","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0145","first-page":"107","article-title":"Nalokson nesespray kan redusere risikoen for d\u00f8delige heroinoverdoser","volume":"21","author":"Lobmaier","year":"2011","journal-title":"Norw. J. Epidemiol."},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0150","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.drugalcdep.2016.04.007","article-title":"Utilizing a train-the-trainer model for multi-site naloxone distribution programs","volume":"163","author":"Madah-Amiri","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0155","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1300\/J069v25n03_11","article-title":"Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths","volume":"25","author":"Maxwell","year":"2006","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0160","first-page":"309","article-title":"From evidence to policy: the Scottish national naloxone programme","volume":"19","author":"McAuley","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0165","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/add.13326","article-title":"Are take-home naloxone programmes effective?: Systematic review utilizing application of the Bradford Hill criteria","volume":"111","author":"McDonald","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0170","series-title":"Harm Reduction Database Wales: Take Home Naloxone 2014\u20132015","author":"Morgan","year":"2015"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0175","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/add.13027","article-title":"Naloxone\u2013does over-antagonism matter? Evidence of iatrogenic harm after emergency treatment of heroin\/opioid overdose","volume":"110","author":"Neale","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0180","unstructured":"Norwegian Directorate of Health, 2014. National Overdose Strategy 2014\u20132017. Oslo, Norway."},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0185","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1080\/10826080701801261","article-title":"Evaluation of a naloxone distribution and administration program in New York City","volume":"43","author":"Piper","year":"2008","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0190","series-title":"Statistics Norway (SSB)","author":"Population and population changes","year":"2014"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0195","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1080\/10903120903144866","article-title":"Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose","volume":"13","author":"Robertson","year":"2009","journal-title":"Prehosp. Emerg. Care"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0200","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/add.12961","article-title":"Predictors of participant engagement and naloxone utilization in a community-based naloxone distribution program","volume":"110","author":"Rowe","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0205","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/jurban\/jti053","article-title":"Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study","volume":"82","author":"Seal","year":"2005","journal-title":"J. Urban Health"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0210","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1136\/bmj.312.7044.1435","article-title":"Heroin overdose: the case for take-home naloxone","volume":"312","author":"Strang","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0215","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/add.13209","article-title":"Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?","volume":"111","author":"Strang","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0220","unstructured":"The Drug Situation in Norway in 2014, 2015. Annual report to the European Monitoring Centre for Drugs and Drug Addiction SIRUS, Oslo."},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0225","unstructured":"The Human Medicines Amendment (No. 3), 2015. No. 1503. Retrieved from http:\/\/www.naloxone.org.uk\/index.php\/lawpolicy\/law\/uklaw1 on December 5, 2016."},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0230","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.drugpo.2008.03.002","article-title":"Evaluation of the Staying Alive programme: training injection drug users to properly administer naloxone and save lives","volume":"20","author":"Tobin","year":"2009","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0235","series-title":"Statusrapport 2015: Mot gensene for vekst og nytte? (Report No. 1)","author":"Waal","year":"2016"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0240","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.drugpo.2009.01.003","article-title":"Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA","volume":"21","author":"Wagner","year":"2010","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0245","doi-asserted-by":"crossref","first-page":"f174","DOI":"10.1136\/bmj.f174","article-title":"Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis","volume":"346","author":"Walley","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0250","first-page":"631","article-title":"Opioid overdose prevention programs providing naloxone to laypersons \u2212 United States, 2014","volume":"64","author":"Wheeler","year":"2015","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"10.1016\/j.drugalcdep.2016.12.013_bib0255","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/08897077.2015.1132294","article-title":"Barriers to implementation of opioid overdose prevention programs in Ohio","volume":"37","author":"Winstanley","year":"2015","journal-title":"Subst. Abus."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871617300315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871617300315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T14:32:56Z","timestamp":1589725976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871617300315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":51,"alternative-id":["S0376871617300315"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.12.013","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid widespread distribution of intranasal naloxone for overdose prevention","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}